Compass Wealth Management LLC Sells 42,772 Shares of Medtronic PLC $MDT

Compass Wealth Management LLC lessened its stake in Medtronic PLC (NYSE:MDT) by 96.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,379 shares of the medical technology company’s stock after selling 42,772 shares during the quarter. Compass Wealth Management LLC’s holdings in Medtronic were worth $131,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of MDT. Norges Bank purchased a new position in Medtronic in the second quarter worth about $1,432,698,000. Vanguard Group Inc. lifted its position in Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after acquiring an additional 1,895,165 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Medtronic by 332.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after purchasing an additional 1,148,803 shares during the last quarter. Laurel Wealth Advisors LLC boosted its stake in Medtronic by 8,779.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after purchasing an additional 1,057,618 shares during the last quarter. Finally, Altrinsic Global Advisors LLC increased its holdings in shares of Medtronic by 47.7% in the 2nd quarter. Altrinsic Global Advisors LLC now owns 2,688,334 shares of the medical technology company’s stock worth $234,342,000 after purchasing an additional 868,256 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of NYSE MDT opened at $100.71 on Wednesday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a market capitalization of $129.12 billion, a price-to-earnings ratio of 27.15, a price-to-earnings-growth ratio of 2.65 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average of $99.52 and a 200 day moving average of $95.48.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period last year, the firm earned $1.26 earnings per share. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Barclays increased their price objective on Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a research report on Thursday, January 8th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. TD Cowen reissued a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Citigroup increased their price objective on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Finally, Leerink Partners set a $120.00 target price on shares of Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Fourteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).